1. Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)
- Author
-
Michio Nakamura, Taro Funakoshi, Shigeki Kataoka, Takahiro Horimatsu, Yoshitaka Nishikawa, Takeshi Matsubara, Takuro Mizukami, Tomoyuki Goto, Kenji Tsuchihashi, Eishi Baba, Takehiko Tsumura, Yoshiaki Mihara, Tetsuya Hamaguchi, Motoko Yanagita, and Manabu Muto
- Subjects
Anti-vascular endothelial growth factor therapy ,Gastrointestinal cancer ,Proteinuria ,Urine protein/creatinine ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Monitoring proteinuria is important for the management of patients with cancer treated with anti-vascular endothelial growth factor (VEGF) or anti-VEGF receptor (VEGFR) inhibitors (VEGF/Ri). Here we investigated the difference between the urine protein/creatinine ratio (UPCR) and a qualitative value test (QV) on the decision making of treatment continuation and the usefulness of UPCR testing in patients with gastrointestinal cancer treated with anti-VEGF/Ri. Methods From January 2017 to December 2018, a survey was conducted based on the medical records of patients with gastrointestinal cancer with a QV of ≥2+ during the use of anti-VEGF/Ri at seven Japanese institutions participating in the Onco-nephrology Consortium. The primary endpoint was the ratio of the worst UPCR
- Published
- 2022
- Full Text
- View/download PDF